The Guggenheim is hoping finally to open its outpost in Abu Dhabi, 20 years after it announced plans to do so. The museum will consider modernism from a global perspective https://t.co/SLn6weIIDV ...

Group 1 - M&A volumes have increased by 47% so far this year, with a strong finish expected due to improved policy clarity and easing interest rates [1][2] - The first quarter saw a nearly 10% decline in volumes, but the second half of the year has shown significant strength [2] - Approximately 25% of all deals over $5 billion last year had an AI-related theme, indicating a transformative impact on the M&A landscape [3] Group 2 - Current M&A activity is focused on core AI infrastructure, including data centers, network infrastructure, data security, and proprietary data sets [4] - Future M&A activity is expected to move downstream, focusing on applications that utilize AI capabilities beyond just technology [5] - Expansionary monetary policy is correlated with increased deal activity, and a potential rate cut could unlock further M&A opportunities [5][6] Group 3 - The current M&A environment is characterized as a strategic super cycle, where companies are racing to acquire capabilities in a rapidly transforming world [6]

M&A volumes up 47 so far this year according to Guggenheim. How could the AI boom impact the dealmaking landscape going forward. Joining us this morning is Guggenheim Securities global head of M&A Eric Rusky.Welcome Eric. Good to have you. Thanks for being with us. >> Thanks for having me back.>> Um it does sound like you think we're going to finish strong as far as the year goes. >> Yeah, absolutely. I mean it's important to remember we started the year in a pretty rocky place.You know, volumes were down a ...

Group 1 - Morgan Stanley analysts reiterated an overweight rating on Nvidia with a price target of $250 [1] - Guggenheim analysts raised their price target on Alphabet (GOOG) to $375 from $330, maintaining a buy rating [1]

Art Market Trends - The art market is hoping to end three years of decline with a big week of auctions [1] - Over $1.4 billion worth of art is expected to be sold at auction next week [2] - Increased supply of incredible works of art is coming up for auction [3] - Demand levels have been setting records, including bidders per lot and sell-through rates [3] Key Auction Items & Estimates - A Klimt portrait of Elizabeth Letter is estimated at $150 million [4] - Maurizio Catalan's solid gold toilet, "America," contains 220 lbs of gold, worth approximately $13 million based on gold prices [6] - The art market anticipates the gold toilet could sell for a multiple of its material value [7] Notable Collectors & Pieces - Works from the collection of the late Leonard Louder and Jay and Cindy Pritzker will be featured at Sibies [4] - Christy's will auction a classic Monet water lily and a Rothko painting [5] - Steve Cohen, a hedge fund manager, is rumored to be the buyer of the gold toilet [8] Contextual Information - The first gold toilet was at the Guggenheim in 2016 and was later stolen and melted down from Blenhan Palace in England [12] - Lower interest rates and a rising stock market are expected to boost demand in the art market [2]

Financial Data and Key Metrics Changes - Q3 subscription revenue grew 19% to $286 million, representing 96% of total revenue [24][4] - Confluent Cloud revenue increased 24% to $161 million, accounting for 56% of subscription revenue compared to 54% in the previous year [24][4] - Non-GAAP operating margin expanded three percentage points to approximately 10% [4] - Subscription gross margin was 81.8%, above the long-term target of 80% [26] - Operating margin increased 340 basis points to a record 9.7%, exceeding guidance by 270 basis points [26] - Adjusted free cash flow margin increased 450 basis points to 8.2% [26] Business Line Data and Key Metrics Changes - Confluent Platform revenue grew 14% to $125.4 million, driven by demand in financial services [24] - Flink ARR for Confluent Cloud grew more than 70% sequentially, with over 1,000 customers using Flink [31][7] - The number of customers with $100k+ ARR increased to 2,533, up 36 sequentially [27] - The number of customers with $1 million+ ARR increased to 234, representing a growth acceleration of 27% [27] Market Data and Key Metrics Changes - Revenue from the U.S. grew 13% to $172.1 million, while revenue from outside the U.S. grew 29% to $126.4 million [24] - Net retention rate stabilized at 114%, with gross retention rate close to 90% [27] Company Strategy and Development Direction - The company is focused on tightening field alignment to drive more use cases into production and expanding its DSP specialist team for multiproduct selling [6][7] - The partner ecosystem sourced over 25% of new business in the last twelve months, indicating strong growth potential [10][11] - The company aims to position itself as a leader in providing real-time data context for AI applications, emphasizing the importance of data streaming in AI deployment [20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong cloud consumption growth and the overall performance of the data streaming platform [22][36] - The company expects subscription revenue for 2025 to be in the range of $295.5 million to $296.5 million, representing approximately 18% growth [29] - For fiscal year 2025, subscription revenue is expected to be between $1.1135 billion and $1.1145 billion, indicating approximately 21% growth [29] Other Important Information - The company highlighted the successful integration and growth of WarpStream, which has seen eightfold growth in consumption since its acquisition [14][35] - The company has maintained a win rate above 90% in replacing CSP streaming offerings, with average deal sizes more than doubling over the past two quarters [11][12] Q&A Session Summary Question: Insights on go-to-market changes and pipeline conversion trends - Management noted that the specialization model for DSP and field execution improvements have driven strong pipeline progression, with high confidence in the late-stage pipeline [40][41] Question: RPO and CRPO as leading indicators - Management confirmed that RPO is a key leading indicator for the Confluent platform, while for Confluent Cloud, the focus is on new use cases moving into production [45][46] Question: Growth outlook and cannibalization effects - Management indicated that new offerings have proven to be a substantial tailwind, leading to larger deal sizes and increased customer engagement [54] Question: Flink adoption and future business impact - Management expressed excitement about Flink's growth and its potential to drive significant business opportunities in the future [76][78] Question: AI use cases and customer readiness - Management highlighted various AI use cases across industries, emphasizing the importance of data flow and quality in achieving successful AI deployments [86][87]

Core Insights - Eli Lilly & Company (NYSE: LLY) is recognized as one of the best non-tech stocks to buy, supported by hedge fund interest [1] - Guggenheim has reaffirmed its Buy rating on Eli Lilly with a price target of $875 [2] - Strong demand for tirzepatide in diabetes and obesity treatment, along with the upcoming launch of orforglipron, is expected to drive global growth [3] Financial Performance - Eli Lilly reported a gross profit margin of 82.64% and a revenue increase of 36.83% year-over-year [3] Regulatory Developments - The U.S. FDA authorized Guardant Health's Guardant360 CDx as a companion diagnostic for Eli Lilly's breast cancer medication Inluriyo, aiding in the identification of patients with advanced breast cancer and ESR1 mutations [4] Market Position - Eli Lilly's advancements in the metabolic and oncology sectors, combined with analyst confidence and regulatory approvals, reinforce its status as a leading global pharmaceutical company [5]

We're back. Stocks are lower today after the S&P and NASDAQ both hit record highs earlier in the session. Here with where to invest right now, Annne Walsh, CIO of Guggenheim.Welcome. It's good to see you. Nice to see you, Scott.How broadly do you feel about the markets right now. What's what's your current view. We're at record highs.We'll just call it that. Right. So, it seems that valuations appear stretched and I think there is a lot of reason to be thoughtful with regard to equities.Um, but I would say ...

Group 1 - The global long-term bond market is experiencing a rebound as investors seek buying opportunities after a sell-off, with U.S. and Japanese 30-year bond yields dropping approximately 20 basis points since early September, and UK yields falling over 10 basis points [1] - The recent decline in long-term bond yields is partly driven by reduced supply, as some countries shift their issuance focus to cheaper short-term bonds, with Japan proposing to cut long-term bond issuance and the UK central bank reducing long-term bond sales in its quantitative tightening plan [1][2] - There is a growing optimism in the long-term bond market, highlighting the significant role of supply concerns in recent sell-offs, despite ongoing worries about rising fiscal deficits [2] Group 2 - Strong economic growth globally is alleviating concerns about fiscal deficits and prompting investors to reconsider long-term interest rate trends, with recommendations for Australian investors to adopt positions that benefit from a flattening yield curve [3] - The Bloomberg Global Aggregate Index indicates that bets on long-term bonds are starting to pay off, with 10-year and longer bonds returning 0.7% this month, outperforming shorter-term bonds [6] - Recent auctions show strong demand for long-term bonds, with Japan's 40-year bonds seeing enthusiastic buying and the strongest demand for 20-year bonds since 2020 [6]

Group 1 - Savara Inc. has been identified as a promising healthcare penny stock, with Guggenheim raising its price target from $8 to $11 while maintaining a Buy rating, following a 16% stock rally year to date [1][2] - The price target increase is supported by positive developments regarding the company's Biologics License Application (BLA), with potential FDA approval expected by mid-next year [2][3] - Savara is transitioning its primary drug manufacturing from GEMA to Fujifilm Diosynth Biotechnologies, which is significant due to Fujifilm's strong FDA track record and new claims indicating a 50% increase in the number of patients in the US with autoimmune pulmonary alveolar proteinosis (aPAP) [3][4] Group 2 - Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases, particularly its lead candidate, molgramostim, an inhaled GM-CSF for aPAP [4]